Changho Choi

List of Publications by Year
in descending order

57 papers	2,596 citations	218677 26 h-index	189892 50 g-index
57 all docs	57 docs citations	57 times ranked	3534 citing authors

#	Article	IF	Citations
1	Optimization of spectrally selective 180Â° radiofrequency pulse timings in Jâ€difference editing (MEGA) of lactate. Magnetic Resonance in Medicine, 2022, 87, 1150-1164.	3.0	2
2	Shimmingâ€"the forgotten child of in-vivo MR?. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 179-181.	2.0	1
3	BIMG-09. GLUTAMINE AND GLYCINE BY MR SPECTROSCOPY IDENTIFY AGGRESSIVE GLIOMAS. Neuro-Oncology Advances, 2021, 3, i2-i3.	0.7	0
4	Spectral fitting strategy to overcome the overlap between 2â€hydroxyglutarate and lipid resonances at 2.25 ppm. Magnetic Resonance in Medicine, 2021, 86, 1818-1828.	3.0	7
5	Preoperative imaging of glioblastoma patients using hyperpolarized 13C pyruvate: Potential role in clinical decision making. Neuro-Oncology Advances, 2021, 3, vdab092.	0.7	9
6	NIMG-29. ELEVATION OF GLUTAMINE AND CITRATE BY MR SPECTROSCOPY IS AN IMAGING BIOMARKER OF RAPID CELL PROLIFERATION IN GLIOMAS. Neuro-Oncology, 2021, 23, vi135-vi135.	1.2	0
7	Magnetic Resonance Spectroscopic Assessment of Isocitrate Dehydrogenase Status inÂGliomas: The New Frontiers of Spectrobiopsy in Neurodiagnostics. World Neurosurgery, 2020, 133, e421-e427.	1.3	16
8	Brief mindfulness training increased glutamate metabolism in the anterior cingulate cortex. NeuroReport, 2020, 31, 1142-1145.	1.2	10
9	Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. Neuro-Oncology, 2020, 22, 1018-1029.	1.2	37
10	Spectroscopic markers of neurodegeneration in the mesial prefrontal cortex predict survival in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 246-251.	1.7	6
11	In vivo MRS measurement of 2â€hydroxyglutarate in patientâ€derived IDHâ€mutant xenograft mouse models versus glioma patients. Magnetic Resonance in Medicine, 2020, 84, 1152-1160.	3.0	11
12	NIMG-24. GLYCINE AND GLUTAMINE BY MR SPECTROSCOPY ARE IMAGING BIOMARKERS OF GLIOMA AGGRESSIVENESS. Neuro-Oncology, 2020, 22, ii152-ii152.	1.2	0
13	False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis. Radiology, 2019, 291, 752-762.	7.3	28
14	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. Neuro-Oncology, 2019, 21, vi28-vi29.	1.2	17
15	NIMG-13. GLYCINE IS A METABOLIC BIOMARKER OF MALIGNANCY IN GLIOMAS: IN VIVO MAGNETIC RESONANCE SPECTROSCOPY STUDY. Neuro-Oncology, 2019, 21, vi164-vi164.	1.2	0
16	NIMG-08. 2-HYDROXYGLUTARATE MAGNETIC RESONANCE SPECTROSCOPY IN BRAINSTEM TUMOR PATIENTS IN VIVO. Neuro-Oncology, 2019, 21, vi163-vi163.	1.2	0
17	3D highâ€resolution imaging of 2â€hydroxyglutarate in glioma patients using DRAGâ€EPSI at 3T in vivo. Magnetic Resonance in Medicine, 2019, 81, 795-802.	3.0	9
18	A randomized, double-blind, placebo-controlled trial of lamotrigine for prescription corticosteroid effects on the human hippocampus. European Neuropsychopharmacology, 2019, 29, 376-383.	0.7	5

#	Article	IF	Citations
19	Distinction of the <scp>GABA</scp> 2.29â€‰ppm resonance using triple refocusing at 3 <scp>T</scp> in vivo. Magnetic Resonance in Medicine, 2018, 80, 1307-1319.	3.0	6
20	Spectrobiopsy in neurodiagnostics: the new era. Neuroradiology, 2018, 60, 129-131.	2.2	7
21	Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. Journal of Neurosurgery, 2018, 128, 391-398.	1.6	62
22	Echoâ€planar spectroscopic imaging with dualâ€readout alternated gradients (DRAGâ€EPSI) at 7 T: Application for 2â€hydroxyglutarate imaging in glioma patients. Magnetic Resonance in Medicine, 2018, 79, 1851-1861.	3.0	30
23	RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi234-vi234.	1.2	4
24	Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomicsâ€”Relevance to Glioma. Frontiers in Neurology, 2018, 9, 33.	2.4	32
25	In vivo detection of 2â€hydroxyglutarate in brain tumors by optimized pointâ€resolved spectroscopy (PRESS) at 7T. Magnetic Resonance in Medicine, 2017, 77, 936-944.	3.0	40
26	Measurement of glycine in healthy and tumorous brain by tripleâ€refocusing MRS at 3ÂT in vivo. NMR in Biomedicine, 2017, 30, e3747.	2.8	9
27	Detection of 2â€hydroxyglutarate in brain tumors by tripleâ€refocusing MR spectroscopy at 3T in vivo. Magnetic Resonance in Medicine, 2017, 78, 40-48.	3.0	28
28	Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. Journal of Clinical Oncology, 2016, 34, 4030-4039.	1.6	157
29	In vivo ¹<scp>H</scp><scp>MRSI</scp> of glycine in brain tumors at 3<scp>T</scp>. Magnetic Resonance in Medicine, 2016, 75, 52-62.	3.0	16
30	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology, 2016, 18, 283-290.	1.2	161
31	¹H MRS characterization of neurochemical profiles in orthotopic mouse models of human brain tumors. NMR in Biomedicine, 2015, 28, 108-115.	2.8	10
32	Proton T₂ measurement and quantification of lactate in brain tumors by MRS at 3 Tesla in vivo. Magnetic Resonance in Medicine, 2015, 73, 2094-2099.	3.0	40
33	Measurement of regional variation of GABA in the human brain by optimized pointâ€resolved spectroscopy at 7â€‰T in vivo. NMR in Biomedicine, 2014, 27, 1167-1175.	2.8	30
34	In vivo detection of citrate in brain tumors by ¹H magnetic resonance spectroscopy at 3T. Magnetic Resonance in Medicine, 2014, 72, 316-323.	3.0	12
35	In vivo T₂ relaxation time measurement with echoâ€time averaging. NMR in Biomedicine, 2014, 27, 863-869.	2.8	7
36	A comparative study of shortâ€and longâ€TE ¹H MRS at 3 T for in vivo detection of 2â€hydroxyglutarate in brain tumors. NMR in Biomedicine, 2013, 26, 1242-1250.	2.8	73

#	Article	IF	Citations
37	Compressive Sensing Could Accelerate¹H MR Metabolic Imaging in the Clinic. Radiology, 2012, 262, 985-994.	7.3	53
38	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nature Medicine, 2012, 18, 624-629.	30.7	711
39	Measurement of glycine in gray and white matter in the human brain in vivo by ¹H MRS at 7.0 T. Magnetic Resonance in Medicine, 2012, 68, 325-331.	3.0	18
40	T₂ measurement of Jâ€coupled metabolites in the human brain at 3T. NMR in Biomedicine, 2012, 25, 523-529.	2.8	72
41	Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR in Biomedicine, 2012, 25, 1177-1186.	2.8	66
42	Metabolism of [Uâ€¹³C]glucose in human brain tumors in vivo. NMR in Biomedicine, 2012, 25, 1234-1244.	2.8	282
43	Phaseâ€adjusted echo time (PATE)â€averaging ¹H MRS: application for improved glutamine quantification at 2.89â€‰T. NMR in Biomedicine, 2012, 25, 1245-1252.	2.8	18
44	Enhanced neurochemical profile of the rat brain using in vivo ¹H NMR spectroscopy at 16.4 T. Magnetic Resonance in Medicine, 2011, 65, 28-34.	3.0	22
45	Measurement of glycine in the human brain in vivo by ¹Hâ€MRS at 3 T: application in brain tumors. Magnetic Resonance in Medicine, 2011, 66, 609-618.	3.0	44
46	Improvement of resolution for brain coupled metabolites by optimized ¹H MRS at 7â€‰T. NMR in Biomedicine, 2010, 23, 1044-1052.	2.8	70
47	Measurement of Nâ€acetylaspartylglutamate in the human frontal brain by ¹Hâ€MRS at 7 T. Magnetic Resonance in Medicine, 2010, 64, 1247-1251.	3.0	43
48	In vivo detection of serine in the human brain by proton magnetic resonance spectroscopy (¹Hâ€MRS) at 7 Tesla. Magnetic Resonance in Medicine, 2009, 62, 1042-1046.	3.0	27
49	Measurement of glycine in human prefrontal brain by pointâ€resolved spectroscopy at 7.0 tesla in vivo. Magnetic Resonance in Medicine, 2009, 62, 1305-1310.	3.0	15
50	Measurement of glutathione in human brain at 3T using an improved double quantum filter in vivo. Journal of Magnetic Resonance, 2009, 198, 160-166.	2.1	14
51	Measurement of glycine in human brain by triple refocusing ¹Hâ€MRS in vivo at 3.0T. Magnetic Resonance in Medicine, 2008, 59, 59-64.	3.0	32
52	Measurement of GABA and contaminants in gray and white matter in human brain in vivo. Magnetic Resonance in Medicine, 2007, 58, 27-33.	3.0	35
53	Measurement of brain glutamate and glutamine by spectrally-selective refocusing at 3 tesla. Magnetic Resonance in Medicine, 2006, 55, 997-1005.	3.0	51
54	Proton spectral editing for discrimination of lactate and threonine 1.31 ppm resonances in human brain in vivo. Magnetic Resonance in Medicine, 2006, 56, 660-665.	3.0	29

#	Article	IF	Citations
55	T2 measurement and quantification of glutamate in human brain in vivo. Magnetic Resonance in Medicine, 2006, 56, 971-977.	3.0	77
56	Brain Î³-aminobutyric acid measurement by proton double-quantum filtering with selectiveJ rewinding. Magnetic Resonance in Medicine, 2005, 54, 272-279.	3.0	29
57	Detection of themyo-inositol 4.06-ppm resonance by selectiveJ rewinding: Application to human prefrontal cortex in vivo. Magnetic Resonance in Medicine, 2005, 54, 1536-1540.	3.0	6